1. Transvenous occlusion of incompetent pelvic veins to treat chronic pelvic pain in women: A randomised controlled trial.
- Author
-
Hansrani, Vivak, Riding, David, Seif, Mourad W., Caress, Ann‐Louise, Payne, Katherine, Ghosh, Jonathan, and McCollum, Charles N.
- Subjects
PELVIC pain ,RANDOMIZED controlled trials ,CHRONIC pain ,VEINS ,SCLEROTHERAPY ,VASCULAR surgery ,COMPRESSION therapy ,VENOGRAPHY - Abstract
Objective: To investigate the effectiveness of transvenous occlusion of incompetent pelvic veins in women presenting with chronic pelvic pain (CPP) in improving symptoms and quality of life. Design: Patient‐blinded randomised controlled trial with objective outcome measures. Results were analysed on an intention‐to‐treat basis. Setting: Gynaecology and Vascular Surgery Services of two teaching hospitals in northwest England. Population: Sixty women aged 18–54 years presenting with CPP after exclusion of other pathology, and who were found to have pelvic vein incompetence. Methods: Participants were randomised and assigned to contrast venography alone or contrast venography plus transvenous occlusion of the incompetent pelvic veins. Main outcome measure: The primary outcome was change in pain score measured using the short‐form McGill Pain Score (SF‐MPQ) and the Visual Analogue Score (VAS) recorded at 12 months post‐randomisation. Secondary outcomes included quality of life using the EQ‐5D instrument, symptomatic improvement and procedure‐related complications. Results: Sixty participants were randomised to transvenous occlusion of incompetent pelvic veins or venography only. At 12 months, median pain scored 2 (3–10) in the intervention group versus 9 (5–22) in controls (p = 0.016). Pain on the VAS scored 15 (0–3) versus 53 (20–71), respectively (p = 0.002). Median EQ‐5D improved after intervention from 0.79 (0.74–0.84) to 0.84 (0.79–1.00; p = 0.008) over 12 months. No major complications were reported. Conclusion: Transvenous occlusion of pelvic vein incompetence reduced pain scores, improved quality of life and diminished symptom burden with no major reported complications. Trial registration: ISRCTN 15091500. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF